This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
FDA approves aducanumab to treat Alzheimer's disease
The FDA cleared Biogen and Eisai's aducanumab Aduhelm as the first new Alzheimer's therapy in nearly two decades, based on modest data showing slowed cognitive decline. The approval carries residual uncertainties, with a 2030 follow up study required and possible market withdrawal if benefits are not confirmed.
MENTIONED IN THIS ARTICLE
Washington
Food and Drug Administration
U.S
Biogen
Japan
Eisai Co
Caleb Alexander
FDA
Alexander
Johns Hopkins University
Aduhelm
Patrizia Cavazzoni
Institute For Clinical and Economic Review
Aducanumab
Richard Hodes
National Institute On Aging
Fdas
Medicare
Michel Vounatsos
Phillip Lynn
Hawaii
Kurt Rehwinkel
Lynn
Rehwinkel